Suzanna Maria Zick

Suzanna Maria Zick

Auto-generated profile, based on publicly available information

Suzanna Maria Zick

University of Michigan, Ann Arbor, MI

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JBJulienne E. Bower
Julienne E. Bower
CLChristina Lacchetti
Christina Lacchetti
YAYesne Alici
Yesne Alici
DBDebra L. Barton
Debra L. Barton
DBDeborah Bruner
Deborah Bruner
KMKaren Mustian
Karen Mustian
ASCO–Society for Integrative Oncology (SIO) Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO-SIO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO and SIO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by providers and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO and SIO do not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more. PURPOSE: To update the ASCO guideline on the management of cancer-related fatigue (CRF) in adult survivors of cancer. METHODS: A multidisciplinary panel of medical oncology, geriatric oncology, internal medicine, psychology, psychiatry, exercise oncology, integrative medicine, behavioral oncology, nursing, and advocacy experts was convened. Guideline development involved a systematic literature review of randomized controlled trials (RCTs) published in 2013-2023. RESULTS: The evidence base consisted of 113 RCTs. Exercise, cognitive behavioral therapy (CBT), and mindfulness-based programs led to improvements in CRF both during and after the completion of cancer treatment. Tai chi, qigong, and American ginseng showed benefits during treatment, whereas yoga, acupressure, and moxibustion helped to manage CRF after completion of treatment. Use of other dietary supplements did not improve CRF during or after cancer treatment. In patients at the end of life, CBT and corticosteroids showed benefits. Certainty and quality of evidence were low to moderate for CRF management interventions. RECOMMENDATIONS: Clinicians should recommend exercise, CBT, mindfulness-based programs, and tai chi or qigong to reduce the severity of fatigue during cancer treatment. Psychoeducation and American ginseng may be recommended in adults undergoing cancer treatment. For survivors after completion of treatment, clinicians should recommend exercise, CBT, and mindfulness-based programs; in particular, CBT and mindfulness-based programs have shown efficacy for managing moderate to severe fatigue after treatment. Yoga, acupressure, and moxibustion may also be recommended. Patients at the end of life may be offered CBT and corticosteroids. Clinicians should not recommend L-carnitine, antidepressants, wakefulness agents, or routinely recommend psychostimulants to manage symptoms of CRF. There is insufficient evidence to make recommendations for or against other psychosocial, integrative, or pharmacological interventions for the management of fatigue. Additional information is available at www.asco.org/survivorship-guidelines .

28 September 2010 in Respiratory Research
Verified
Journal Article
Open access
PDF file
SGShyamala Ganesan
Shyamala Ganesan
AFAndrea N Faris
Andrea N Faris
ACAdam T Comstock
Adam T Comstock
SCSangbrita S Chattoraj
Sangbrita S Chattoraj
ACAsamanja Chattoraj
Asamanja Chattoraj
USUma S Sajjan
Uma S Sajjan
Chronic obstructive pulmonary disease (COPD) is characterized by chronic bronchitis, emphysema and irreversible airflow limitation. These changes are thought to be due to oxidative stress and an imbalance of proteases and antiproteases. Quercetin, a plant flavonoid, is a potent antioxidant and anti-inflammatory agent. We hypothesized that quercetin reduces lung inflammation and improves lung function in elastase/lipopolysaccharide (LPS)-exposed mice which show typical features of COPD, including airways inflammation, goblet cell metaplasia, and emphysema.

22 September 2011 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
SZSuzanna M Zick
Suzanna M Zick
BWBenjamin D Wright
Benjamin D Wright
ASAnanda Sen
Ananda Sen
JAJ Todd Arnedt
J Todd Arnedt
Despite being the most commonly used herbal for sleep disorders, chamomile's (Matricaria recutita) efficacy and safety for treating chronic primary insomnia is unknown. We examined the preliminary efficacy and safety of chamomile for improving subjective sleep and daytime symptoms in patients with chronic insomnia.

2 December 2016 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
SZSuzanna Maria Zick
Suzanna Maria Zick
Justin A. ColacinoJustin A. Colacino
Justin A. Colacino
MCMaria Cornellier
Maria Cornellier
TKTohfa Khabir
Tohfa Khabir
KSKatie Surnow
Katie Surnow
ZDZora Djuric
Zora Djuric

3 June 2011 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
YYYanke Yu
Yanke Yu
SZSuzanna Zick
Suzanna Zick
XLXiaoqin Li
Xiaoqin Li
PZPeng Zou
Peng Zou
BWBenjamin Wright
Benjamin Wright
DSDuxin Sun
Duxin Sun

29 September 2009 in European Journal of Heart Failure
Verified
Journal Article
Closed access
PDF file
SZSuzanna M. Zick
Suzanna M. Zick
BVBonnie Motyka Vautaw
Bonnie Motyka Vautaw
BGBrenda Gillespie
Brenda Gillespie
KAKeith D. Aaronson
Keith D. Aaronson
Aims: Hawthorn’s efficacy when added to contemporary evidence-based heart failure therapy is unknown. We aimed to determine whether hawthorn increases submaximal exercise capacity when added to standard medical therapy. Methods and results: We performed a randomized, double-blind, placebo-controlled trial in 120 ambulatory patients aged ≥18 years with New York Heart Association (NYHA) class II-III chronic heart failure. All patients received conventional medical therapy, as tolerated, and were randomized to either hawthorn 450 mg twice daily or placebo for 6 months. The primary outcome was change in 6 min walk distance at 6 months. Secondary outcomes included quality of life (QOL) measures, peak oxygen consumption, and anaerobic threshold during maximal treadmill exercise testing, NYHA classification, left ventricular ejection fraction (LVEF), neurohormones, and measures of oxidative stress and inflammation. There were no significant differences between groups in the change in 6 min walk distance (P = 0.61), or on measures of QOL, functional capacity, neurohormones, oxidative stress, or inflammation. A modest difference in LVEF favoured hawthorn (P = 0.04). There were significantly more adverse events reported in the hawthorn group (P = 0.02), although most were non-cardiac. Conclusion: Hawthorn provides no symptomatic or functional benefit when given with standard medical therapy to patients with heart failure. This trial is registered in ClinicalTrials.gov ID: NCT00343902.